New Japan PMDA Head Brings Strong Clinical, Patient Focus To Role
Japan PMDA Aims For Smooth Regulatory Flow
Executive Summary
The main priorities for the new chief executive of Japan’s drugs regulator over the next five years include putting patients first by promoting early access while ensuring safety, further strengthening pharmacovigilance as new forms of therapy come through, and increasing collaboration with Asia, as the agency looks to meet the challenges of changing technologies.
You may also be interested in...
Master Key Project Aims To Unlock Japan Rare Cancer Drug Development
Japan's National Cancer Center is progressing a collaborative project with industry to encourage the development of targeted therapies for rare cancers, as part of wider efforts to support early access to personalized oncology drugs.
Daiichi's Novel EZH Candidate Progresses In New Consortium Trial
Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.
Quick Listen: Scrip’s Five Must-Know Things
A resolution in a long-running patent dispute, expansion of coronavirus vaccine production, drug development trends over the past decade, hematological malignancies in a clinical trial, and the last instalment in the Scrip Asks series all feature in this week's podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports